First-pass and high-resolution steady-state magnetic resonance angiography of the peripheral arteries with Gadobenate Dimeglumine: An assessment of feasibility and diagnostic performance

Investigative Radiology

Volumn 46, Issue 5, 2011, Pages 307-316

  Anzidei, Michele ^a   Napoli, Alessandro ^a   Zaccagna, Fulvio ^a   Cavallo Marincola, Beatrice ^a   Zini, Chiara ^b   Kirchin, Miles A ^a   Catalano, Carlo ^a   Passariello, Roberto ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Bracco Imaging SpA   (Italy)

Author keywords

gadobenate dimeglumine; gadolinium contrast agents; magnetic resonance angiography; peripheral arterial occlusive disease; vascular imaging

Indexed keywords

GADOBENATE DIMEGLUMINE; IOMEPROL;

ADULT; AGED; ARTERY OCCLUSION; ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIGITAL SUBTRACTION ANGIOGRAPHY; FEASIBILITY STUDY; FEMALE; FIRST PASS EFFECT; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; OBSERVER VARIATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STEADY STATE;

EID: 79954895995     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3182021879     Document Type: Article

References (56)

1. Randoux B, Marro B, Koskas F, et al. Carotid artery stenosis: prospective comparison of CT, three-dimensional gadolinium-enhanced MR, and conventional angiography. Radiology. 2001;220:179-185. (Pubitemid 32577981)
2. Ouwendijk R, Kock MC, Visser K, et al. Interobserver agreement for the interpretation of contrast-enhanced 3D MR angiography and MDCT angiography in peripheral arterial disease. Am J Roentgenol. 2005;185:1261-1267.
3. Lauffer RB, Parmelee DJ, Dunham SU, et al. Gadofosveset: albumin-targeted contrast agent for MR angiography. Radiology. 1998;207:529-538. (Pubitemid 28259074)
4. Caravan P, Cloutier NJ, Greenfield MT, et al. The interaction of gadofosveset with human serum albumin and its effect on proton relaxation rates. J Am Chem Soc. 2002;124:3152-3162. (Pubitemid 34249987)
5. Anzidei M, Napoli A, Marincola BC, et al. Gadofosveset-enhanced MR angiography of carotid arteries: does steady-state imaging improve accuracy of first-pass imaging? Comparison with selective digital subtraction angiography. Radiology. 2009;251:457-466.
6. Bonel HM, Saar B, Hoppe H, et al. MR angiography of infrapopliteal arteries in patients with peripheral arterial occlusive disease by using Gadofosveset at 3.0 T: diagnostic accuracy compared with selective DSA. Radiology. 2009; 253:879-890.
7. Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol. 1997;32:780-796. (Pubitemid 28053510)
8. Giesel FL, von Tengg-Kobligk H, Wilkinson ID, et al. Influence of human serum albumin on longitudinal and transverse relaxation rates (R1 and R2) of magnetic resonance contrast agents. Invest Radiol. 2006;41:222-228. (Pubitemid 44406182)
9. Anzidei M, Napoli A, Marincola BC, et al. High-resolution steady state magnetic resonance angiography of the carotid arteries: are intravascular agents necessary? Feasibility and preliminary experience with gadobenate dimeglumine. Invest Radiol. 2009;44:784-792.
10. Fontaine R, Kim M, Kieny R. Die chirurgische Behandlung der peripheren Durchblutungsstorungen. Helv Chir Acta. 1954;21:499-533.
11. Saloner D. Determinants of image appearance in contrast-enhanced magnetic resonance angiography: a review. Invest Radiol. 1998;33:488-495. (Pubitemid 30261945)
12. Jou LD, Saloner D. A numerical study of magnetic resonance images of pulsatile flow in a two dimensional carotid bifurcation: a numerical study of MR images. Med Eng Phys. 1998;20:643-652. (Pubitemid 29090696)
13. Hadizadeh DR, Gieseke J, Lohmaier SH, et al. Peripheral MR angiography with blood pool contrast agent: prospective intraindividual comparative study of high-spatial-resolution steady-state MR angiography versus standard-resolution first-pass MR angiography and DSA. Radiology. 2008;249:701-711.
14. Nielsen YW, Eiberg JP, Løgager VB, et al. Whole-body MR angiography with body coil acquisition at 3T in patients with peripheral arterial disease using the contrast agent gadofosveset trisodium. Acad Radiol. 2009;16:654-661.
15. Nielsen YW, Eiberg JP, Løgager VB, et al. Whole-body magnetic resonance angiography with additional steady-state acquisition of the infragenicular arteries in patients with peripheral arterial disease. Cardiovasc Intervent Radiol. 2010;33:484-491.
16. Pintaske J, Martirosian P, Graf H, et al. Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla [erratum in Invest Radiol. 2006;41:859]. Invest Radiol. 2006;41:213-221. (Pubitemid 44406181)
17. Kroencke TJ, Wasser MN, Pattynama PM, et al. Gadobenate dimeglumine-enhanced magnetic resonance angiography of the abdominal aorta and renal arteries. Am J Roentgenol. 2002;179:1573-1582. (Pubitemid 35386663)
18. Wikstrom J, Wasser MN, Pattynama PM, et al. Gadobenate dimeglumine-enhanced magnetic resonance angiography of the pelvic arteries. Invest Radiol. 2003;38:504-515. (Pubitemid 36875547)
19. Schneider G, Ballarati C, Grazioli L, et al. Gadobenate dimeglumine-en-hanced MR angiography: diagnostic performance of four doses for detection and grading of carotid, renal, and aortoiliac stenosis compared to digital subtraction angiography. JMagn Reson Imaging. 2007;26:1020-1032. (Pubitemid 47548164)
20. Kreitner KF, Kunz RP, Herber S, et al. MR angiography of the pedal arteries with gadobenate dimeglumine, a contrast agent with increased relaxivity, and comparison with selective intraarterial DSA. J Magn Reson Imaging. 2008; 27:78-85.
21. Anzalone N, Scomazzoni F, Castellano R, et al. Carotid artery stenosis: intra-individual correlations of unenhanced 3D time-of-flight MR angiography, contrast-enhanced MR angiography, conventional DSA, and rotational angiography for detection and grading. Radiology. 2005;236:204-213. (Pubitemid 40853314)
22. Soulez G, Pasowicz M, Benea G, et al. Renal artery stenosis evaluation: diagnostic performance of gadobenate dimeglumine-enhanced MR angiogra-phy-comparison with DSA. Radiology. 2008;247:273-285.
23. Thurnher S, Miller S, Schneider G, et al. Diagnostic performance of gado-benate dimeglumine enhanced MR angiography of the iliofemoral and calf arteries: a large-scale multicenter trial. Am J Roentgenol. 2007;189:1223-1237. (Pubitemid 350033021)
24. Knopp MV, Schoenberg SO, Rehm C, et al. Assessment of gadobenate dimeglumine for magnetic resonance angiography: phase I studies. Invest Radiol. 2002;37:706-715. (Pubitemid 35429192)
25. Pediconi F, Fraioli F, Catalano C, et al. Gadobenate dimeglumine (Gd-BOPTA) vs gadopentetate dimeglumine (Gd-DTPA) for contrast-enhanced magnetic resonance angiography (MRA): improvement in intravascular signal intensity and contrast-to-noise ratio. Radiol Med (Torino). 2003;106:87-93. (Pubitemid 37254345)
26. Völk M, Strotzer M, Lenhart M, et al. Renal time-resolved MR angiography: quantitative comparison of gadobenate dimeglumine and gadopentetate dime-glumine with different doses. Radiology. 2001;220:484-488. (Pubitemid 32667190)
27. Prokop M, Schneider G, Vanzulli A, et al. Contrast-enhanced MR angiogra-phy of the renal arteries: blinded multicenter crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology. 2005; 234:399-408. (Pubitemid 40139908)
28. Attenberger UI, Michaely HJ, Wintersperger BJ, et al. Three-dimensional contrast-enhanced magnetic-resonance angiography of the renal arteries: nterindividual comparison of 0. 2 mmol/kg gadobutrol at 1.5 T and 0.1 mmol/kg gadobenate dimeglumine at 3.0 T. Eur Radiol. 2008;18:1260-1268.
29. Bültmann E, Erb G, Kirchin MA, et al. Intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for contrast-enhanced MR angiography of the supraaortic vessels at 3 Tesla. Invest Radiol. 2008;43:695-702.
30. Knopp MV, Giesel FL, von Tengg-Kobligk H, et al. Contrast-enhanced MR angiography of the run-off vasculature: intraindividual comparison of gado-benate dimeglumine with gadopentetate dimeglumine. J Magn Reson Imaging. 2003;17:694-702. (Pubitemid 36665874)
31. Wyttenbach R, Gianella S, Alerci M, et al. Prospective blinded evaluation of Gd-DOTA- versus Gd-BOPTA-enhanced peripheral MR angiography, as compared with Digital Subtraction Angiography. Radiology. 2003;227:261-269. (Pubitemid 36384208)
32. Gerretsen S, le Maire T, Miller S, et al. Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for MR angiography of the peripheral arteries. Radiology. 2010;255:988-1000.
33. Schneider G, Pasowicz M, Vymazal J, et al. Multicenter intraindividual comparison of gadobenate dimeglumine and gadofosveset for contrast-enhanced magnetic resonance angiography of the renal arteries. Am J Roentgenol. 2010; 195:476-485.
34. Tongdee R, Narra VR, McNeal G, et al. Hybrid peripheral 3D contrast-enhanced MR angiography of calf and foot vasculature. Am J Roentgenol. 2006;186:1746-1753. (Pubitemid 46112541)
35. Pereles FS, Collins JD, Carr JC, et al. Accuracy of stepping-table lower extremity MR angiography with dual-level bolus timing and separate calf acquisition: hybrid peripheral MR angiography. Radiology. 2006;240:283-290. (Pubitemid 43902620)
36. Berg F, Bangard C, Bovenschulte H, et al. Feasibility of peripheral contrast-enhanced magnetic resonance angiography at 3.0 Tesla with a hybrid technique: comparison with digital subtraction angiography. Invest Radiol. 2008; 43:642-649.
37. Broome DR, Girguis MS, Baron PW, et al. Gadodiamide-associated nephro-genic systemic fibrosis: why radiologists should be concerned. Am J Roentgenol. 2007;188:586-592. (Pubitemid 46167763)
38. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology. 2007;243:148-157. (Pubitemid 46579705)
39. Kallen AJ, Jhung MA, Cheng S, et al. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study. Am J Kidney Dis. 2008;51:966-975. (Pubitemid 351711602)
40. Abujudeh HH, Kaewlai R, Kagan A, et al. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients. Radiology. 2009;253:81-89.
41. O'Hare A, Johansen K. Lower-extremity peripheral arterial disease among patients with end-stage renal disease. J Am Soc Nephrol. 2001;12:2838-2847. (Pubitemid 33115433)
42. Matsumae T, Abe Y, Murakami G, et al. Determinants of arterial wall stiffness and peripheral artery occlusive disease in nondiabetic hemodialysis patients. Hypertens Res. 2007;30:377-385. (Pubitemid 46958887)
43. FDA. New warnings required on use of gadolinium-based contrast agents. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements. Accessed September 9, 2010.
44. Bhagavathula N, Dame MK, Dasilva M, et al. Fibroblast response to gadolinium: role for platelet-derived growth factor receptor. Invest Radiol. 2010: 45:769-777.
45. Dasilva M, Deming MO, Fligiel SE, et al. Responses of human skin in organ culture and human skin fibroblasts to a gadolinium-based MRI contrast agent: comparison of skin from patients with end-stage renal disease and skin from healthy subjects. Invest Radiol. 2010;45:733-739.
46. Haylor J, Dencausse A, Vickers M, et al. Nephrogenic gadolinium biodistri-bution and skin cellularity following a single injection of Omniscan in the rat. Invest Radiol. 2010;45:507-512.
47. Wang CC, Liang HL, Hsiao CC, et al. Single-dose time-resolved contrast enhanced hybrid MR angiography in diagnosis of peripheral arterial disease: compared with digital subtraction angiography. J Magn Reson Imaging. 2010; 32:935-942.
48. Spinazzi A, Lorusso V, Pirovano G, et al. Safety, tolerance, biodistribution and MR imaging enhancement of the liver with gadobenate dimeglumine. Acad Radiol. 1999;6:282-291.
49. Rapp JH, Wolff SD, Quinn SF, et al. Aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease: safety and efficacy of gadofosveset-enhanced MR angiography-multicenter comparative phase III study. Radiology. 2005;236:71-78. (Pubitemid 40853296)
50. Goyen M, Edelman M, Perreault P, et al. MR angiography of aortoiliac occlusive disease: a phase III study of the safety and effectiveness of the blood-pool contrast agent gadofosveset. Radiology. 2005;236:825-833. (Pubitemid 41170843)
51. Achenbach M, Figiel JH, Burbelko M, et al. Prospective comparison of image quality and diagnostic accuracy of 0.5 molar gadobenate dimeglumine and 1.0 molar gadobutrol in contrast-enhanced run-off magnetic resonance angiogra-phy of the lower extremities. J Magn Reson Imaging. 2010;32:1166-1171.
52. Bleicher AG, Kanal E. A serial dilution study of gadolinium-based MR imaging agents. Am J Neuroradiol. 2008;29:668-673. (Pubitemid 351571544)
53. Yrjänä SK, Vaara T, Karttunen A, et al. Pulse repetition time and contrast enhancement: simulation study of Gd-BOPTA and conventional contrast agent at different field strengths. Invest Radiol. 2008;43:267-275. (Pubitemid 351416770)
54. Mell M, Tefera G, Thornton F, et al. Clinical utility of time-resolved imaging of contrast kinetics (TRICKS) magnetic resonance angiography for infra-geniculate arterial occlusive disease. J Vasc Surg. 2007;45:543-548. (Pubitemid 46281530)
55. Voth M, Haneder S, Huck K, et al. Peripheral magnetic resonance angiogra-phy with continuous table movement in combination with high spatial and temporal resolution time-resolved MRA With a total single dose (0.1 mmol/kg) of gadobutrol at 3.0 T. Invest Radiol. 2009;44:627-633.
56. Bhat H, Yang Q, Zuehlsdorff S, et al. Contrast-enhanced whole-heart coronary magnetic resonance angiography at 3 T using interleaved echo planar imaging. Invest Radiol. 2010;45:458-464.